First and Last Name/s of Presenters

Hailey ErwinFollow

Participation Type

Paper Talk

Mentor/s

Professor Thomas Terleph

Location

Panel H: University Commons UC 105

Start Day/Time

4-20-2018 2:00 PM

End Day/Time

4-20-2018 3:00 PM

Abstract

Stem cell transplants have become common treatment for certain types of cancer including multiple myeloma and acute lymphoblastic leukemia. There are two types of stem cells that are derived from different places. Autologous stem cells are taken from the body of a sick patient and put back into the same patient after treatment. Allogeneic stem cells come from a donor and are given to a person who is sick as treatment. The main focus of this paper is to analyze the two different type of stem cell treatments and to determine which one is a more effective method in treating patients with blood related cancers.

The biggest risks associated with autologous stem cell transplant are rejection of the cells and reinjecting cancer cells back into the patient if the extracted stem cells were not properly purged. The biggest risk associated with allogeneic stem cell transplant are rejection of the new stem cells and infection from them. There have been more benefits associated with allogeneic stem cells because of their ability to potentially fight off the disease. This phenomena is known as the graft vs. cancer effect, it is when the immune system cells from the donor work to kill the cancer in the recipient. The autologous stem cells can prolong someone’s life but cannot keep the cancer from coming back. Allogeneic stem cells have more risks associate with them, however the benefits outweigh the risk making this the more efficient stem cell treatment.

College

College of Arts and Sciences

College and Major available

Biology

Creative Commons License

Creative Commons Attribution-Noncommercial 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.

Share

COinS
 
Apr 20th, 2:00 PM Apr 20th, 3:00 PM

Medical Advantages of Allogeneic vs Autologous Stem Cell Transplants as Treatment in Blood Related Cancer Patients

Panel H: University Commons UC 105

Stem cell transplants have become common treatment for certain types of cancer including multiple myeloma and acute lymphoblastic leukemia. There are two types of stem cells that are derived from different places. Autologous stem cells are taken from the body of a sick patient and put back into the same patient after treatment. Allogeneic stem cells come from a donor and are given to a person who is sick as treatment. The main focus of this paper is to analyze the two different type of stem cell treatments and to determine which one is a more effective method in treating patients with blood related cancers.

The biggest risks associated with autologous stem cell transplant are rejection of the cells and reinjecting cancer cells back into the patient if the extracted stem cells were not properly purged. The biggest risk associated with allogeneic stem cell transplant are rejection of the new stem cells and infection from them. There have been more benefits associated with allogeneic stem cells because of their ability to potentially fight off the disease. This phenomena is known as the graft vs. cancer effect, it is when the immune system cells from the donor work to kill the cancer in the recipient. The autologous stem cells can prolong someone’s life but cannot keep the cancer from coming back. Allogeneic stem cells have more risks associate with them, however the benefits outweigh the risk making this the more efficient stem cell treatment.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.